B. Riley Financial Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price

Eton Pharmaceuticals (NASDAQ:ETON) had its price target raised by B. Riley Financial from $26.00 to $31.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also recently weighed in on ETON. Wall Street Zen cut Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $39.33.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $22.32 on Friday. The company has a market capitalization of $598.58 million, a PE ratio of -123.99 and a beta of 1.19. Eton Pharmaceuticals has a 12 month low of $11.09 and a 12 month high of $23.00. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19. The stock’s fifty day simple moving average is $16.72 and its 200 day simple moving average is $17.38.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.66%. The business had revenue of $21.28 million during the quarter, compared to analyst estimates of $20.58 million. On average, research analysts predict that Eton Pharmaceuticals will post -0.14 EPS for the current year.

Institutional Trading of Eton Pharmaceuticals

Several hedge funds have recently bought and sold shares of ETON. State of Alaska Department of Revenue bought a new stake in Eton Pharmaceuticals during the 3rd quarter valued at $30,000. Ameritas Investment Partners Inc. acquired a new position in Eton Pharmaceuticals during the second quarter worth $37,000. Quarry LP bought a new position in shares of Eton Pharmaceuticals in the third quarter valued at $37,000. Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals during the second quarter valued at about $41,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at about $44,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Key Headlines Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.